CML Kidney Cancer - 2010 - Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer.


Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma - September, 2011
Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. - August, 2011
Experience with sorafenib and the elderly patient. - July, 2011
Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. - June, 2011
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted - May, 2011
Endostatin gene therapy enhances the efficacy of IL-2 in suppressing metastatic renal cell carcinoma in mice. - April, 2011
Percutaneous renal cryoablation: local control at mean 26 months of followup - March, 2011
Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors - February, 2011
Genomic expression and single-nucleotide polymorphism profiling discriminates chromophobe renal cell carcinoma and oncocytoma. - January, 2011
Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? - December, 2010
Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. - November, 2010
Incidence of brain metastases in renal cell carcinoma treated with sorafenib. - October, 2010
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. - September, 2010
Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. - August, 2010
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. - July, 2010
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. - June, 2010
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2 and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open label randomized trial. - May, 2010
Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. - April, 2010
MicroRNA profiling of human kidney cancer subtypes. - March, 2010
Synergistic effect of sorafenib and sunitinib with enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines. - February, 2010
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy - October, 2009
How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. - September, 2009
MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells. - August, 2009
Randomized Phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. - July, 2009
Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. - June, 2009
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. - May, 2009
Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. - April, 2009

© Remedica 2012. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the copyright owners. While every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to make it clear that the material contained in the publication represents a summary of the independent evaluations and opinions of the authors and contributors. As a consequence, the board, publishers, and any supporting company accept no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither do they endorse the content of the publication or the use of any drug or device in a way that lies outside its current licensed application in any territory. For detailed information on any drugs or devices discussed in this publication, readers are advised to consult the manufacturer’s prescribing information.

Produced and published by Remedica Medical Education and Publishing Limited.

May 23, 2012

CLOSE

To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader.

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us

CML Kidney Cancer

» Advanced search

Paper of the Month - August, 2010

Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer.

Sato T, Nakashima A, Guo L et al.

View Archive »

Post Page On

SUBMIT AN ARTICLE


0 rating

May 23, 2012 CLOSE To subscribe to updates from this journal click Confirm. Updates will be displayed in your default RSS reader. Produced and published by Remedica Medical Education and Publishing Limited. » Contact us

CML Kidney Cancer » Advanced search